Document is current
Any future updates will be listed below
-
Authors
,
Tachibana, Takayoshi https://orcid.org/0000-0002-7780-4459
Ishizaki, Takuma
Takahashi, Satoshi
Najima, Yuho
Kimura, Shun-ichi
Sakaida, Emiko https://orcid.org/0000-0002-7254-1928
Onizuka, Makoto
Mori, Takehiko https://orcid.org/0000-0002-8176-4760
Fujisawa, Shin
Fujiwara, Shin-ichiro
Saito, Takeshi
Hagihara, Maki
Aotsuka, Nobuyuki
Gotoh, Moritaka
Usuki, Kensuke
Tsukada, Nobuhiro
Kanda, Junya https://orcid.org/0000-0002-6704-3633
Kanamori, Heiwa
Kanda, Yoshinobu
Okamoto, Shinichiro
- License Information
-
More Information
Article History
Received: 30 August 2019
Revised: 2 September 2019
Accepted: 5 September 2019
First Online: 19 September 2019
Compliance with ethical standards
:
: KU reports grants and personal fees from MSD K.K., Sumitomo Dainippon Pharma, Pfizer Japan, and Celgene Corporation, grants from Astellas Pharma, Otsuka, Kyowa Kirin, GlaxoSmithKline K.K., Sanofi K.K., Shire Japan, SymBio Pharmaceuticals Limited., Daiichi Sankyo, Boehringer-Ingelheim Japan, and Janssen Pharmaceutical K.K, and personal fees from Novartis, Ono Pharmaceutical, Takeda Pharmaceuticals, Chugai Pharmaceutical, Nippon Shinyaku, and Mochida Pharmaceutical. Other authors declare that they have no conflict of interest.
